{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:57:21Z","timestamp":1775055441509,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.jid.2015.12.036","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T16:00:33Z","timestamp":1453478433000},"page":"798-808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Increased, but Functionally Impaired, CD14+ HLA-DR\u2013\/low Myeloid-Derived Suppressor Cells in Psoriasis: A Mechanism of Dysregulated T Cells"],"prefix":"10.1016","volume":"136","author":[{"given":"David C.","family":"Soler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew B.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Fiessinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Debanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Groft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin D.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2015.12.036_bib1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/PPO.0000000000000006","article-title":"Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer","volume":"19","author":"Albeituni","year":"2013","journal-title":"Cancer J"},{"key":"10.1016\/j.jid.2015.12.036_bib2","first-page":"301","article-title":"Efalizumab in the treatment of psoriasis","volume":"1","author":"Boehncke","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.jid.2015.12.036_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1710-1492-9-37","article-title":"A\u00a0detailed phenotypic analysis of immune cell populations in the bronchoalveolar lavage fluid of atopic asthmatics after segmental allergen challenge","volume":"9","author":"Boomer","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/cmi.2012.15","article-title":"New insights of T cells in the pathogenesis of psoriasis","volume":"9","author":"Cai","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib5","first-page":"16","article-title":"Psoriasis and cardiovascular risk factors: increased serum myeloperoxidase and corresponding immunocellular overexpression by Cd11b(+) CD68(+) macrophages in skin lesions","volume":"6","author":"Cao","year":"2013","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jid.2015.12.036_bib6","doi-asserted-by":"crossref","first-page":"e1047580","DOI":"10.1080\/2162402X.2015.1047580","article-title":"Anergic bone marrow Vgamma9Vdelta2 T cells as early and long-lasting\u00a0markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma","volume":"4","author":"Castella","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jid.2015.12.036_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","article-title":"Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function","volume":"32","author":"Condamine","year":"2011","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","article-title":"Regulation of tumor metastasis by myeloid-derived suppressor cells","volume":"66","author":"Condamine","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jid.2015.12.036_bib9","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2015.12.036_bib10","article-title":"CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients","author":"Dubinski","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jid.2015.12.036_bib11","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.4049\/jimmunol.180.12.7898","article-title":"Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion","volume":"180","author":"Dugast","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib12","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.1986.03380220076026","article-title":"Cyclosporine improves psoriasis in a double-blind study","volume":"256","author":"Ellis","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2015.12.036_bib13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"345","author":"Ellis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2015.12.036_bib14","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4049\/jimmunol.1203535","article-title":"Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis","volume":"191","author":"Fujii","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib15","doi-asserted-by":"crossref","first-page":"e54895","DOI":"10.1371\/journal.pone.0054895","article-title":"Photo(chemo)therapy reduces circulating Th17 cells and restores circulating regulatory T cells in psoriasis","volume":"8","author":"Furuhashi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2015.12.036_bib16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00262-011-1028-0","article-title":"Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13","volume":"60","author":"Gabitass","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jid.2015.12.036_bib17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/0008-5472.CAN-06-3037","article-title":"The terminology issue for myeloid-derived suppressor cells","volume":"67","author":"Gabrilovich","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2015.12.036_bib18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/jid.2010.12","article-title":"Psoriasis and cardiovascular risk: strength in numbers","volume":"130","author":"Gelfand","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2015.12.036_bib20","first-page":"1007","volume":"131","author":"Gelfand","year":"2011","journal-title":"Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol"},{"key":"10.1016\/j.jid.2015.12.036_bib21","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.2174\/138161206777947731","article-title":"LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics","volume":"12","author":"Giblin","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jid.2015.12.036_bib22","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.4049\/jimmunol.1402307","article-title":"Chronic psoriatic skin inflammation leads to increased monocyte adhesion and aggregation","volume":"195","author":"Golden","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib23","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.4049\/jimmunol.0803721","article-title":"IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells","volume":"183","author":"Goodman","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib24","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.4049\/jimmunol.1001455","article-title":"Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression","volume":"186","author":"Goodman","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.intimp.2011.01.003","article-title":"Myeloid derived suppressor cells in human diseases","volume":"11","author":"Greten","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jid.2015.12.036_bib26","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1158\/1078-0432.CCR-12-1108","article-title":"Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma","volume":"18","author":"Gros","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2015.12.036_bib27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1053\/j.gastro.2008.06.032","article-title":"Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway","volume":"135","author":"Haile","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jid.2015.12.036_bib28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/157488706776876436","article-title":"Efalizumab: a biological agent for the treatment of psoriasis","volume":"1","author":"Hodulik","year":"2006","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.jid.2015.12.036_bib29","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1182\/blood-2010-11-317321","article-title":"Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells","volume":"117","author":"Hoechst","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jid.2015.12.036_bib30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/j.gastro.2008.03.020","article-title":"A\u00a0new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells","volume":"135","author":"Hoechst","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jid.2015.12.036_bib31","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jid.2015.12.036_bib32","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.4049\/jimmunol.1002650","article-title":"Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction","volume":"187","author":"Kim","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2326-6066.CIR-14-0013","article-title":"Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes","volume":"2","author":"Kitano","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jid.2015.12.036_bib34","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2011.06.011","article-title":"Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials","volume":"66","author":"Lebwohl","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2015.12.036_bib35","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.4049\/jimmunol.1000901","article-title":"Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells","volume":"185","author":"Lechner","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1479-5876-9-90","article-title":"Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines","volume":"9","author":"Lechner","year":"2011","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jid.2015.12.036_bib37","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2015.12.036_bib38","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.4049\/jimmunol.179.8.5071","article-title":"The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema","volume":"179","author":"Marhaba","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib39","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1067\/mjd.2001.117852","article-title":"A\u00a0multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis","volume":"45","author":"Martin","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2015.12.036_bib40","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jid.2015.12.036_bib41","doi-asserted-by":"crossref","first-page":"775.e1","DOI":"10.1016\/j.amjmed.2011.03.028","article-title":"Attributable risk estimate of severe psoriasis on major cardiovascular events","volume":"124","author":"Mehta","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jid.2015.12.036_bib42","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archdermatol.2011.119","article-title":"Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET\/CT): a pilot study","volume":"147","author":"Mehta","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2015.12.036_bib43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000131424","volume":"10","author":"Nestle","year":"2008","journal-title":"Psoriasis. Curr Dir Autoimmun"},{"key":"10.1016\/j.jid.2015.12.036_bib44","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"Nestle","year":"2009","journal-title":"Psoriasis. N Engl J Med"},{"key":"10.1016\/j.jid.2015.12.036_bib45","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia\u00a0enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2015.12.036_bib46","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2015.12.036_bib47","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1158\/0008-5472.CAN-09-3767","article-title":"Kiessling R Immature immunosuppressive CD14+HLA-DR-\/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign","volume":"70","author":"Poschke","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2015.12.036_bib48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000238305","article-title":"Circulating CD4+CD25 bright FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients","volume":"219","author":"Quaglino","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2015.12.036_bib49","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.2106","article-title":"Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection","volume":"16","author":"Said","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2015.12.036_bib50","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.4049\/jimmunol.1201018","article-title":"Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth","volume":"189","author":"Schlecker","year":"2012","journal-title":"J\u00a0Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.jid.2015.12.036_bib51","first-page":"4","article-title":"Efalizumab, a reversible T-cell modulator for psoriasis","volume":"9","author":"Shear","year":"2006","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.jid.2015.12.036_bib52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.clim.2013.06.007","article-title":"Psoriasis patients exhibit impairment of the high potency CCR5(+) T regulatory cell subset","volume":"149","author":"Soler","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/nyas.12469","article-title":"Myeloid-derived suppressor cell heterogeneity in human cancers","volume":"1319","author":"Solito","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jid.2015.12.036_bib54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev.iy.02.040184.001251","article-title":"Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships","volume":"2","author":"Strober","year":"1984","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib56","first-page":"503","article-title":"Alefacept in the treatment of psoriasis","volume":"26","author":"Sugiyama","year":"2008","journal-title":"ClinDermatol"},{"key":"10.1016\/j.jid.2015.12.036_bib57","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jid.2015.12.036_bib58","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.4049\/jimmunol.177.7.4917","article-title":"An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12\/IL-23 in psoriasis","volume":"177","author":"Toichi","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib59","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1172\/JCI60083","article-title":"STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients","volume":"123","author":"Vasquez-Dunddel","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2015.12.036_bib60","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4049\/jimmunol.1202088","article-title":"Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8\/A9 proinflammatory proteins","volume":"190","author":"Wang","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2015.12.036_bib61","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00109-012-0916-x","article-title":"Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells","volume":"90","author":"Wu","year":"2012","journal-title":"J\u00a0Mol Med"},{"key":"10.1016\/j.jid.2015.12.036_bib62","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.ajpath.2011.06.028","article-title":"Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis","volume":"179","author":"Wu","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jid.2015.12.036_bib63","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1378\/chest.11-0205","article-title":"Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension","volume":"141","author":"Yeager","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jid.2015.12.036_bib64","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1023\/A:1006708607666","article-title":"Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor","volume":"17","author":"Young","year":"1999","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.jid.2015.12.036_bib65","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2133.2007.08359.x","article-title":"Functional characterization of CD4+CD25+ regulatory T cells differentiated in\u00a0vitro from bone marrow-derived haematopoietic cells of psoriasis patients with a family history of the disorder","volume":"158","author":"Zhang","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2015.12.036_bib66","doi-asserted-by":"crossref","first-page":"e63775","DOI":"10.1371\/journal.pone.0063775","article-title":"eripheral blood MDSCs, IL-10 and IL-12 in children with asthma and their importance in asthma development","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X16003523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X16003523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T20:42:24Z","timestamp":1542919344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X16003523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0022202X16003523"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2015.12.036","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased, but Functionally Impaired, CD14+ HLA-DR\u2013\/low Myeloid-Derived Suppressor Cells in Psoriasis: A Mechanism of Dysregulated T Cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2015.12.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}